Tazemetostat hydrobromide is a Small Molecule owned by Epizyme, and is involved in 53 clinical trials, of which 12 were completed, 31 are ongoing, and 10 are planned.

Tazemetostat hydrobromide acts as an inhibitor of EZH2. EZH2 control gene expression and promote tumorigenesis via methylating histone H3 at lysine 27 (H3K27). EZH2 is the catalytic subunit of polycomb repressive complex 2 (PRC2), which is a highly conserved histone methyltransferase. The drug candidates by inhibiting the function of EZH2 prevent the EZH2 mediated down regulation of tumor suppressor factors.

The revenue for Tazemetostat hydrobromide is expected to reach a total of $2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Tazemetostat hydrobromide NPV Report.

Tazemetostat hydrobromide is originated and owned by Epizyme. Ipsen and Hutchmed China are the other companies associated in development or marketing of Tazemetostat hydrobromide.

Tazemetostat hydrobromide Overview

Tazemetostat hydrobromide (Tazverik) is an anti-neoplastic agent. It is formulated as film coated tablets for oral route of administration. Tazverik is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma who are not eligible for complete resection, for adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, and for adult patients with R/R FL who have no satisfactory alternative treatment options. Tazemetostat hydrobromide is under development for the treatment of pancreatic cancer, colorectal cancer, recurrent or metastatic head and neck squamous-cell carcinoma, marginal zone lymphoma, non-Hodgkin lymphoma, mantle cell lymphoma, metastatic castration-resistant prostate cancer, b-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, chordoma, primary mediastinal B-cell lymphoma (EZH2), peripheral T-cell lymphomas (PTCL), other relapsed or refractory solid tumors such as INI1-negative tumors including malignant rhabdoid tumor (MRT), rhabdoid tumor of the kidney (RTK), atypical teratoid / rhabdoid tumor (ATRT), epithelioid malignant peripheral nerve sheath tumor, neuroblastoma, extraskeletal myxoid chondrosarcoma, myoepithelial carcinoma, hepatocellular carcinoma, squamous non-small cell lung cancer, relapsed or refractory mesothelioma (pleural, peritoneal, pericardial, tunica vaginalis), renal medullary carcinoma, urothelial carcinoma, small-cell lung cancer and 3 unspecified indications. The drug candidate is administered orally. It is a selective small molecule inhibitor of protein methyltransferase EZH2. It was also under development for chronic myeloid leukaemia, endometrial cancer, ovarian cancer, peritoneal cancer and uterine cancer. It was also under development for the treatment of synovial sarcoma, rhabdomyosarcoma, hematological tumor, Non-Hodgkin lymphoma, solid tumor and lymphoma.

Ipsen Overview

Ipsen is a global specialty biopharmaceutical company engaged in the manufacturing and distribution of drugs for the treatment of cancer, rare diseases and neurological diseases, including specialty pharmaceutical products. The company develops and commercializes novel medicines for cancer, neuroscience and rare diseases and also offers products to treat gastrointestinal disorders, neurodegenerative pathologies and rheumatic diseases. Ipsen sells its drugs through a network of distributors and directly to hospitals in a few countries. The company operates its research and development facilities in Paris-Saclay, France; Oxford, the UK; and Cambridge, the US. The company offers products in Europe, North America, Asia and rest of the world. Ipsen is headquartered in Paris, France.

The company reported revenues of (Euro) EUR2,999.1 million for the fiscal year ended December 2021 (FY2021), an increase of 11.6% over FY2020. In FY2021, the company’s operating margin was 28.4%, compared to an operating margin of 19.7% in FY2020. In FY2021, the company recorded a net margin of 21.6%, compared to a net margin of 20.4% in FY2020.

Quick View – Tazemetostat hydrobromide

Report Segments
  • Innovator (NME)
Drug Name
  • Tazemetostat hydrobromide
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
  • Undisclosed
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.